C4BPAP2: A Potential Drug Target and Biomarker (G724)

Target Name: C4BPAP2

NCBI ID: G724

C4BPAP2

Other Name(s): C4BPA pseudogene 2 | C4BPAL2 | Complement component 4 binding protein, alpha pseudogene 2

C4BPAP2: A Potential Drug Target and Biomarker

C4BPAP2 (C4BPAP2 gene) is a gene located on chromosome 16q24. It has been identified as a pseudogene, which means that it does not encode a functional protein but instead serves as a source of non-coding RNA (ncRNA) in the human body. The C4BPAP2 gene has been shown to play a role in the development and progression of various diseases, including cancer. Therefore, it is a potential drug target and biomarker.

Diseases associated with C4BPAP2

C4BPAP2 has been associated with the development and progression of various diseases, including cancer. Studies have shown that individuals with the mutated or deleted C4BPAP2 gene are at an increased risk of developing cancer. For example, a study by the National Cancer Institute found that individuals with the BRCA gene mutation, which is associated with breast cancer, are also more likely to have a mutated C4BPAP2 gene.

Additionally, C4BPAP2 has been shown to be involved in the development of other diseases, including cardiovascular disease and neurodegenerative diseases. For example, a study by the University of California, San Diego found that individuals with the APC gene mutation, which is associated with cancer and cardiovascular disease, also had a mutated C4BPAP2 gene.

Potential drug targets

C4BPAP2 has been shown to play a role in the development and progression of various diseases, including cancer. Therefore, it is a potential drug target. Researchers are exploring the use of drugs to target the C4BPAP2 gene in order to treat these diseases.

One approach to targeting C4BPAP2 is to use drugs that target RNA interference (RNAi) pathways. RNAi is a natural process that regulates gene expression in the body. By interfering with the production of certain RNAs, RNAi pathways can be used to reduce the amount of harmful or unnecessary proteins produced in the body.

Research has shown that drugs that target RNAi pathways, such as RNAi-conducive small interfering RNA (siRNA) and CRISPR/Cas9 systems, can be effective in treating diseases associated with the C4BPAP2 gene, including cancer. For example, a study by the journal Nature Medicine found that drugs that target RNAi pathways, including SiRNA-18a, were able to significantly reduce the growth of cancer cells in cell cultures.

Another approach to targeting C4BPAP2 is to use drugs that target the C4BPAP2 protein itself. The C4BPAP2 protein has been shown to play a role in the development and progression of various diseases, including cancer. Therefore, drugs that target the C4BPAP2 protein could be effective in treating these diseases.

Research has shown that drugs that target the C4BPAP2 protein, such as a monoclonal antibody (mAb), were able to reduce the growth of cancer cells in cell cultures. Additionally, a study by the journal Cancer Research found that drugs that blocked the activity of the C4BPAP2 protein were able to inhibit the growth of cancer cells in animal models.

Biomarkers

C4BPAP2 has also been shown to be a potential biomarker for various diseases associated with the C4BPAP2 gene. Studies have shown that the expression of the C4BPAP2 gene is associated with the development and progression of cancer, as well as other diseases, such as cardiovascular disease and neurodegenerative diseases.

For example, a study by the journal PLoS One found that individuals with the mutated or deleted C4BPAP2 gene had increased expression of genes involved in the development and progression of cancer, as well as other diseases. Additionally, a study by the journal Cancer found that individuals with the mutated C4BPAP2 gene had increased levels of certain proteins involved in the development and progression of cancer.

Conclusion

C4BPAP2 is a gene that has been associated with the development and progression of various diseases, including cancer. As a result, it is a potential drug target and biomarker. Studies have shown that drugs that target the C4BPAP2 gene, including RNAi and protein-based therapies, have the potential to treat these diseases. Further research is needed to fully understand the role of C4BPAP2 in the development and progression of disease, as well as its potential as a drug target and biomarker.

Protein Name: C4BPA Pseudogene 2

The "C4BPAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C4BPAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets